Latest filings (excl ownership)
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
5 Apr 24
20-F
2023 FY
Annual report (foreign)
5 Apr 24
6-K
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
4 Apr 24
6-K
Current report (foreign)
29 Feb 24
6-K
GENFIT Announces 2024 Financial Calendar
17 Jan 24
6-K
Current report (foreign)
11 Jan 24
6-K
Current report (foreign)
8 Dec 23
6-K
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
7 Dec 23
6-K
Current report (foreign)
6 Dec 23
6-K
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
16 Nov 23
6-K
Current report (foreign)
13 Nov 23
6-K
GENFIT Reports Third Quarter 2023 Financial Information
9 Nov 23
6-K
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
6 Nov 23
6-K
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
26 Sep 23
6-K
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
20 Sep 23
6-K
Current report (foreign)
20 Sep 23
6-K
GENFIT to Participate in Upcoming Investor Conferences
5 Sep 23
6-K
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
10 Aug 23
6-K
Current report (foreign)
12 Jul 23
6-K
Current report (foreign)
30 Jun 23
6-K
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
7 Jun 23
6-K
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
31 May 23
6-K
Current report (foreign)
24 May 23
6-K
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology
23 May 23
6-K
GENFIT Reports First Quarter 2023 Financial Information1
11 May 23
6-K
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program
9 May 23
EFFECT
Notice of effectiveness
5 May 23
CORRESP
Correspondence with SEC
2 May 23
6-K
GENFIT Announces Publication of Extra-Financial Performance Report 2022
28 Apr 23
UPLOAD
Letter from SEC
25 Apr 23
6-K
Current report (foreign)
19 Apr 23
6-K
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
18 Apr 23
F-3
Shelf registration (foreign)
18 Apr 23
S-8
Registration of securities for employees
18 Apr 23
20-F
2022 FY
Annual report (foreign)
18 Apr 23
6-K
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update
14 Apr 23
6-K
Current report (foreign)
28 Feb 23
6-K
Current report (foreign)
30 Jan 23